Search Results for "Screening"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Screening. Results 101 to 110 of 140 total matches.

Elafibranor (Iqirvo) for Primary Biliary Cholangitis

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024  (Issue 1718)
of reproductive potential should be screened for pregnancy before starting treatment with elafibranor; use ...
Elafibranor (Iqirvo – Ipsen), a peroxisome proliferator-activated receptor (PPAR) agonist, has been granted accelerated approval by the FDA for treatment of primary biliary cholangitis (PBC) in adults. It is indicated for use in combination with ursodeoxycholic acid (ursodiol, UDCA; Urso, and others) in patients with an inadequate response to UDCA alone and as monotherapy in those unable to tolerate UDCA.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):202-4   doi:10.58347/tml.2024.1718b |  Show IntroductionHide Introduction

Routine Immunization for Adult

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 1990  (Issue 819)
to hepatitis B are now widely available. All pregnant women should be screened for HBsAg, because hepatitis B ...
Six vaccines are recommended for routine use in adults living in the USA (Guide for Adult Immunization, 2nd ed, Philadelphia:American College of Physicians, 1990). Immunization recommendations for travel outside the USA were published in The Medical Letter, volume 32, page 33, April 6, 1990.
Med Lett Drugs Ther. 1990 Jun 1;32(819):54-6 |  Show IntroductionHide Introduction

Certolizumab (Cimzia) for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008  (Issue 1297)
% of placebo-treated subjects. One certolizumab-treated patient with a negative PPD skin test at screening ...
The FDA has approved the marketing of certolizumab pegol (Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is the third TNF blocker approved for this indication.
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81-2 |  Show IntroductionHide Introduction

Viloxazine ER (Qelbree) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021  (Issue 1627)
disorder. Patients should be screened for their risk of developing bipolar disorder before starting ...
The FDA has approved viloxazine extended-release capsules (Qelbree – Supernus) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. Viloxazine is the second selective norepinephrine reuptake inhibitor to be approved in the US for treatment of ADHD; atomoxetine (Strattera, and generics) was approved in 2002.
Med Lett Drugs Ther. 2021 Jun 28;63(1627):98-100 |  Show IntroductionHide Introduction

A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine

   
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021  (Issue 1640)
The treatment period was preceded by a 28-day screening period in which patients treated migraine attacks ...
The FDA has approved Trudhesa (Impel Neuropharma), a new dihydroergotamine nasal spray product, for acute treatment of migraine with or without aura in adults. Another dihydroergotamine nasal spray (Migranal, and generics) has been available for many years for the same indication.
Med Lett Drugs Ther. 2021 Dec 27;63(1640):204-7 |  Show IntroductionHide Introduction

Ublituximab (Briumvi) for Relapsing Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023  (Issue 1671)
be screened for HBV and low serum immunoglobulin levels before starting treatment with ublituximab. Serum ...
The FDA has approved the recombinant chimeric anti-CD20 antibody ublituximab-xiiy (Briumvi – TG Therapeutics) for IV treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Two other anti-CD20 antibodies, IV ocrelizumab (Ocrevus) and SC ofatumumab (Kesimpta), are also FDA-approved for these indications.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):36-8   doi:10.58347/tml.2023.1671c |  Show IntroductionHide Introduction

Drugs for Psoriatic Arthritis

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019  (Issue 1588)
with active or chronic infections. Screening for exposure to TB is recommended before starting anti-TNF ...
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment of psoriatic arthritis have recently been published.
Med Lett Drugs Ther. 2019 Dec 30;61(1588):203-10 |  Show IntroductionHide Introduction

Cord Blood Banks

   
The Medical Letter on Drugs and Therapeutics • Oct 01, 2001  (Issue 1114)
, for a fee. MATERNAL SCREENING AND TESTING — Potential donors are excluded if the maternal blood sample ...
Pregnant women now often receive promotional material from private cord blood banks urging them to save and store their babies' cord blood.
Med Lett Drugs Ther. 2001 Oct 1;43(1114):84-6 |  Show IntroductionHide Introduction

Natalizumab (Tysabri) for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • May 05, 2008  (Issue 1285)
Prescribing Program (800-456-2255), a mechanism for safety monitoring. Screening for PML is required ...
Natalizumab (Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF). Initially approved in 2004 for the treatment of multiple sclerosis (MS), natalizumab was temporarily withdrawn from the market after 3 patients developed progressive multifocal leukoencephalopathy (PML). It is now available for treatment of both MS and CD through a restricted distribution program.
Med Lett Drugs Ther. 2008 May 5;50(1285):34-6 |  Show IntroductionHide Introduction

Tenofovir Alafenamide (Vemlidy) for Hepatitis B

   
The Medical Letter on Drugs and Therapeutics • Jan 02, 2017  (Issue 1511)
B/C). Patients should be screened for HIV-1 infection before starting TAF; those co-infected ...
The FDA has approved tenofovir alafenamide (Vemlidy – Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first single-drug product containing tenofovir alafenamide (TAF), a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir, to become available; several combination products containing TAF are approved for treatment of HIV-1 infection. Tenofovir disoproxil fumarate (TDF; Viread – Gilead), another tenofovir prodrug, has been used for many years for treatment of chronic HBV infection; a generic...
Med Lett Drugs Ther. 2017 Jan 2;59(1511):6-8 |  Show IntroductionHide Introduction